Vivos Therapeutics | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 6.783 M

Revenue: As of FY2025 Q3, the actual value is USD 6.783 M, beating the estimate of USD 4.712 M.

EPS: As of FY2025 Q3, the actual value is USD -0.49.

Financial Metrics by Segment

Segment Revenue

• The report does not provide specific segment revenue details.

Operational Metrics

• The report does not provide specific operational metrics such as net income, gross margin, operating profit, operating margin, or operating costs.

Cash Flow

• The report does not provide specific cash flow details.

Unique Metrics

• The report does not provide specific unique metrics.

Outlook / Guidance

• The report does not provide specific outlook or guidance details.

Revenue

• Revenue for the third quarter of 2025 was $6.8 million, a significant increase from $3.9 million in the same period of 2024. For the nine months ended September 30, 2025, revenue was $13.6 million compared to $11.3 million in 2024. This growth was driven by higher product and service revenue, particularly from the acquisition of The Sleep Center of Nevada (SCN), which contributed $2.2 million in diagnostic sleep testing revenue and $1.3 million in treatment center revenue during the third quarter.

Gross Profit and Margin

• Gross profit for the third quarter of 2025 was $3.9 million, up from $2.3 million in the same quarter of 2024. For the nine months ended September 30, 2025, gross profit was $7.6 million compared to $6.9 million in 2024. The gross margin declined to 58% in the third quarter of 2025 from 60% in the third quarter of 2024, and to 55% for the nine months ended September 30, 2025, from 61% in the same period in 2024, due to pricing discounts and shifts in product and service mix.

Operating Expenses and Loss

• Operating expenses for the third quarter of 2025 were $8.7 million, a 74% increase from $5.0 million in the same period of 2024, primarily due to increased general and administrative expenses related to the SCN acquisition. For the nine months ended September 30, 2025, operating expenses were $21.1 million compared to $15.3 million in 2024. The operating loss for the third quarter of 2025 increased to $4.7 million from $2.6 million in the third quarter of 2024, and to $13.5 million for the nine months ended September 30, 2025, from $8.4 million in 2024.

Cash and Cash Equivalents

• As of September 30, 2025, cash and cash equivalents were $3.1 million, down from $6.3 million as of December 31, 2024. Stockholders’ equity was $2.5 million compared to $8.0 million at the end of 2024.

Outlook / Guidance

• Vivos Therapeutics, Inc. plans to continue expanding its operations by adding new sleep optimization teams and exploring additional acquisitions or alliances with medical sleep providers. The company anticipates that these efforts will eventually reduce cash burn and create the potential for profitable operations. Vivos is also looking to extend its model into additional major markets beyond Las Vegas.